OVID
Closed
Ovid Therapeutics Inc
0.316
-0.014 (-4.24%)
Last Update: 01 Jul 2025 23:23:00
Yesterday: 0.3299
Day's Range: 0.3123 - 0.3336
Send
sign up or login to leave a comment!
When Written:
2.53
Ovid Therapeutics Inc. is a biopharmaceutical company that focuses on developing treatments for rare neurological disorders. The company was founded in 2014 and is headquartered in New York City. Ovid's lead product candidate is OV101, a drug that is being developed for the treatment of Angelman syndrome and Fragile X syndrome, two rare genetic disorders that affect cognitive and behavioral function. OV101 is currently in Phase 2 clinical trials for both indications. Ovid also has a pipeline of other drug candidates in development for rare neurological disorders, including CDKL5 deficiency disorder and tuberous sclerosis complex. The company is committed to advancing innovative therapies that address unmet medical needs and improve the lives of patients and their families. Ovid is publicly traded on the NASDAQ stock exchange under the ticker symbol OVID.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








